SZSE:300937 (China)
Â
Class A
Â¥
21.57
(+1.75%)
Jun 7
Current and historical daily PE Ratio for Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd (
) from 2021 to Jun 08 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical stock (SZSE:300937) PE ratio as of Jun 08 2024 is 55.88.
More Details
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd (SZSE:300937) PE Ratio (TTM) Chart
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd (SZSE:300937) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 814
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-09 | 55.9 | 2024-04-01 | 65.5 |
| 2024-06-07 | 55.9 | 2024-03-29 | 64.1 |
| 2024-06-06 | 54.9 | 2024-03-28 | 63.0 |
| 2024-06-05 | 58.5 | 2024-03-27 | 39.0 |
| 2024-06-04 | 60.8 | 2024-03-26 | 39.3 |
| 2024-06-03 | 61.2 | 2024-03-25 | 39.5 |
| 2024-05-31 | 63.1 | 2024-03-22 | 40.3 |
| 2024-05-30 | 62.5 | 2024-03-21 | 41.3 |
| 2024-05-29 | 60.8 | 2024-03-20 | 41.7 |
| 2024-05-28 | 59.1 | 2024-03-19 | 41.2 |
| 2024-05-27 | 59.0 | 2024-03-18 | 41.0 |
| 2024-05-24 | 58.2 | 2024-03-15 | 39.9 |
| 2024-05-23 | 57.6 | 2024-03-14 | 39.8 |
| 2024-05-22 | 59.3 | 2024-03-13 | 39.7 |
| 2024-05-21 | 58.0 | 2024-03-12 | 40.1 |
| 2024-05-20 | 58.6 | 2024-03-11 | 39.3 |
| 2024-05-17 | 58.6 | 2024-03-08 | 38.9 |
| 2024-05-16 | 59.1 | 2024-03-07 | 37.6 |
| 2024-05-15 | 62.0 | 2024-03-06 | 37.8 |
| 2024-05-14 | 61.5 | 2024-03-05 | 38.3 |
| 2024-05-13 | 59.3 | 2024-03-04 | 39.9 |
| 2024-05-10 | 60.6 | 2024-03-01 | 38.2 |
| 2024-05-09 | 62.5 | 2024-02-29 | 37.6 |
| 2024-05-08 | 61.2 | 2024-02-28 | 36.2 |
| 2024-05-07 | 61.9 | 2024-02-27 | 39.7 |
| 2024-05-06 | 60.8 | 2024-02-26 | 38.7 |
| 2024-04-30 | 59.1 | 2024-02-23 | 37.5 |
| 2024-04-29 | 59.2 | 2024-02-22 | 37.0 |
| 2024-04-26 | 56.8 | 2024-02-21 | 35.8 |
| 2024-04-25 | 55.8 | 2024-02-20 | 35.6 |
| 2024-04-24 | 57.3 | 2024-02-19 | 34.2 |
| 2024-04-23 | 57.7 | 2024-02-08 | 32.8 |
| 2024-04-22 | 57.6 | 2024-02-07 | 30.0 |
| 2024-04-19 | 57.8 | 2024-02-06 | 32.3 |
| 2024-04-18 | 56.5 | 2024-02-05 | 31.4 |
| 2024-04-17 | 56.1 | 2024-02-02 | 35.6 |
| 2024-04-16 | 52.1 | 2024-02-01 | 37.5 |
| 2024-04-15 | 56.9 | 2024-01-31 | 38.2 |
| 2024-04-12 | 59.5 | 2024-01-30 | 40.6 |
| 2024-04-11 | 60.3 | 2024-01-29 | 42.3 |
| 2024-04-10 | 60.0 | 2024-01-26 | 43.4 |
| 2024-04-09 | 62.2 | 2024-01-25 | 44.0 |
| 2024-04-08 | 61.4 | 2024-01-24 | 42.3 |
| 2024-04-03 | 64.2 | 2024-01-23 | 41.7 |
| 2024-04-02 | 65.3 | 2024-01-22 | 41.5 |
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd (SZSE:300937) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd
ISIN : CNE100004CV9
Share Class Description:
SZSE:300937: Class ACompare
Compare
Traded in other countries / regions
300937.China IPO Date
2021-01-27Description
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd provides convenient, efficient and low-cost medical circulation services for the vast community medical terminals and primary medical institutions. It offers various products such as respiratory system, cardiovascular and neurological drugs, biological product, rheumatism and bone injuries and other medicines, cardiovascular and neurological drugs and others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers